Important Notes
| LOI Deadline extended to Mon, Sept 26 |
| Applicants are strongly advised to read the instructions and eligibility criteria before starting an application. |
| Letters of Intent (LOI) are available on the Foundant Technologies Website. |
| You must be invited to submit a full application. |
Anticipated Timeline
| July 19, 2022 | Letter of Intent Period Opens |
| September 26, 2022 | Deadline for Letter of Intent due by 11:59 pm Eastern Time |
| November 23, 2022 | Invitation from Scientific Grant Review Committee for Full Applications |
| January 10, 2023 | Full Application Deadline due by 11:59 pm Eastern Time |
| March 2023 | Grantee Notification |
| April/May 2023 | Grant Start Date |
Current Partner Grant Opportunities
 |
ATS/Alveolar Capillary Dysplasia (ACDMPV) Research Grant1 grant available |
|
Target Audience: |
|
The focus of this research grant is proposals that advance research in the area of alveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV). Proposals may be basic, translational, or clinical science research projects. Procedures or proposed therapeutic trials may be new, based on recent biochemical or pharmacological evidence, or in preliminary stages of clinical investigation. Evaluation of proposals will include careful consideration of protocol design, objectiveness of parameters measured, and statistical evaluation proposed. Protocols that will focus on treatment (rather than cause, early detection or diagnosis) will be given priority. Applicants may request up to $25,000 per year for two years. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or for subject enrollment fees directly related to the project or other allowable costs. Indirect costs will not be paid to the sponsoring institution. |
|
Award-specific eligibility: |
|
Co-funded by the ACDA and The David Ashwell Foundation. The ACDA and The David Ashwell Foundation are respectively USA- and UK-based not for profit charitable organizations founded by parents of infants with ACDMPV. Funds are raised by parents, families, and friends globally with the aim of increasing scientific knowledge about ACDMPV and therapeutic strategies related thereto. |
| |
|
|
ATS/Alpha-1 Foundation Research Grant |
|
1 grant available |
|
Target Audience: |
|
The focus of this research grant is proposals that have a high likelihood to advance the understanding of Alpha-1. Applications are encouraged from faculty members at any stage of their academic career. Applicants may request up to $40,000 per year for two years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution. |
|
Award-specific eligibility: |
| Co-funded by the ATS and the Alpha-1 Foundation. |
 |
ATS/CSL Behring Research Award in Acute Respiratory Distress Syndrome (ARDS) |
| 1 grant available $50,000 per year for 1 year |
| Target Audience: Early-stage investigators interested in research on ARDS |
| The focus of this research grant is proposals that advance understanding of acute respiratory distress syndrome (ARDS). Applicants may request up to $50,000 for 1 year. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Early-stage investigators (as defined here) • Must meet eligibility requirements for all grants found here |
| Fully funded by CSL Behring. |
| |
|
|
ATS/Fisher & Paykel Healthcare Research Grant in Nasal High Flow |
| 1 grant available $50,000 per year for 2 years |
| Target Audience: Early-stage investigators interested in research on respiratory support with nasal high flow therapy in hospital patients |
| The focus of this research grant is proposals on respiratory support with nasal high flow therapy in hospital patients. Nasal high flow (NHF) therapy refers to a typical range from 20 to 70 L/min of heated, humidified gas delivered to the nares via purposely designed nasal cannula. Flow settings and fraction of delivered supplemental oxygen during the therapy vary depending on the patient’s level of compliance and severity of disease. There has been a recent rapid uptake in the use of NHF in acute care settings, primarily to treat hypoxemic respiratory failure, and the therapy has been extensively used around the world during the COVID-19 pandemic. Apart from efficient oxygenation due to the prevention of room air entrainment, NHF provides respiratory support that may be seen in the reduction of the breathing frequency and the work of breathing. Positive airway pressure and the reduction of re-breathing caused by the clearance of expired gas in the upper airways are believed to be the key mechanisms that may improve the ventilation efficiency during NHF. Saturation with water of heated gas maintains hydration of the airway surface liquid and preserves mucociliary function. |
| NHF therapy is increasingly used in stable patients with lung disease or post-surgery who require support during unassisted breathing with little or no supplemental oxygen. Fisher & Paykel Healthcare, in collaboration with the American Thoracic Society, seeks to offer a research award to investigators interested in studying these potential benefits of NHF in hospital patients. The prospective study could be aimed at better understanding the mechanisms of action of this therapy, or on achieving improvements in a variety of likely outcomes. |
| Applicants may request up to $50,000 per year for 2 years. NHF equipment and consumables can be provided for the study by Fisher & Paykel Healthcare at no cost. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Early-stage investigators (as defined here) • Must meet eligibility requirements for all grants found here |
Fully funded by Fisher & Paykel Healthcare. |
Review Process
Please note that after you submit your application it will be reviewed by Research Program staff. If there are any problems or if these guidelines have not been followed, your proposal will be un-submitted. Please make sure that you check your email after you submit your application so that any outstanding issues may be addressed as quickly as possible.
The ATS Scientific Grant Review Committee (SGRC)* will review the applications at the end of February 2023. The membership of the SGRC is listed on the ATS Website and additional ad hoc reviewers will be invited to participate as needed. Funding decisions will be made on the basis of scientific merit, novelty, and responsiveness to the purpose of the specific grant program.
*previously known as the Scientific Advisory Committee (SAC)
ATS Policy on Additional Grant Funding
Simultaneous submission of grants with scientific overlap is allowed, but if multiple applications are funded, then the applicant must notify the Research Program within one month of formal notification of award. A subcommittee of the SGRC will assess the degree of overlap. In the case of significant scientific overlap, the applicant will have to choose between the ATS Foundation research grant and the other grant. Budgetary overlap is not allowed.
If your question is not answered in the FAQ, contact the Research Program at researchprogram@thoracic.org.
